Methods of using IL-21 for adoptive immunotherapy and identification of tumor antigens
Methods for preparing ex vivo T cell cultures using IL-21 compositions for use in adoptive immunotherapy are described. Addition of IL-21 to cultures of non-terminally differentiated T cells population, either isolated or present in peripheral blood mononuclear cells are exposed to one or more tumor antigens, and in the presence of IL-21 compositions and antigen presenting cells (APCs), the resulting T cell population has an enhanced antigen-specificity, and can be reintroduced into the patient. Methods are also disclosed for identifying tumor antigens by culturing T cell populations exposed to IL-21 compositions and APCs in the presence of tumor material.
1. A method of preparing a T cell population comprising:
isolating peripheral blood mononuclear cells (PBMCs) from a biological sample;
identifying PBMCs having a histocompatible phenotype to a subject having a tumor;
selecting a CD8+ human T cell population from the identified PBMCs;
depleting CD45RO+ cells from the selected CD8+ human T cell population;
selecting CD62L+ cells from the CD45RO+ cells depleted CD8+ human T cell population to obtain a naïve CD8+ human T cell population having a phenotype of CD8+CD45RO-CD45RA+CD62L+,
co-culturing tumor material isolated from the subject with the naïve CD8+ human T cell population in the presence of an IL-21 composition and antigen presenting cells (APCs); and
expanding the cells in culture.
2. The method of claim 1 , wherein the PBMCs are autologous.
3. The method of claim 1 , wherein after the step of co-culturing the tumor material with the naive CD8+ human T cell population, the naive CD8+ human T cells are enriched for tumor material specific T cells.
4. A method of preparing a naive CD8+ human T cell population comprising:
obtaining a biological sample containing T cells;
identifying a T cell population having a histocompatible phenotype to a subject having a tumor;
selecting a CD8+ human T cell population from the identified T cell population;
depleting CD45RO+ cells from the selected CD8+ human T cell population;
selecting CD62L+ cells from the CD45RO+ cells depleted CD8+ human T cell population to obtain the naïve CD8+ human T cell population having a phenotype of CD8+CD45RO-CD45RA+CD62L+,
co-culturing tumor material from the subject with the naive CD8+ human T cell population in the presence of an IL-21 composition and APCs; and
expanding these cells in culture.
5. The method of claim 4 , wherein the T cell population is autologous.
6. The method of claim 4 , wherein the tumor material comprises total RNA, lysed tumor cells or apoptotic bodies.
7. The method of claim 4 , wherein after the step of co-culturing the tumor material with the naive CD8+ human T cell population, the naive CD8+ human T cells are enriched for tumor material specific T cells.
8. The method of claim 4 , further comprising:
reintroducing the cells back into the subject.
9. The method of claim 8 , wherein after the step of co-culturing the tumor material with the naive CD8+ human T cell population, the naive CD8+ human T cells are enriched for tumor material specific T cells.
10. A method of preparing a non-terminally differentiated CD8+ human T cell population for use in adoptive immunotherapy comprising:
obtaining a biological sample containing T cells;
identifying a T cell population having a histocompatible phenotype to a subject having a tumor;
selecting a non-terminally differentiated CD8+ human T cell population from the identified T cell population;
depleting CD45RO+ cells from the selected CD8+ human T cell population;
selecting CD62L+ cells from the CD45RO+ cells depleted CD8+ human T cell population to obtain the non-terminally differentiated CD8+ human T cell population having a phenotype of CD8+CD45RO-CD45RA+CD62L+,
co-culturing tumor material from the subject with the non-terminally differentiated CD8+ human T cell population in the presence of an IL-21 composition and APCs; and
expanding these cells in culture.
11. The method of claim 10 , wherein the T cell population is autologous.
12. The method of claim 1 , further comprising reintroducing the cells back into the subject.
13. The method of claim 10 , wherein after the step of co-culturing the tumor material with the non-terminally differentiated CD8+ human T cell population, the non-terminally differentiated CD8+ human T cells are enriched for tumor material specific T cells.
14. The method of claim 10 , further comprising reintroducing the cells back into the subject.